The benefits of drugs such as donanemab, aducanumab and lecanemab are proving harder to quantify than potential harms, experts say
It was heralded in news articles as a “breakthrough”, a “turning point” and a “gamechanger” for Alzheimer’s disease. Some experts went so far as to call the drug, donanemab, the “beginning of the end” for the debilitating condition.
Pharmaceutical company Eli Lilly in May 2023 released data from a clinical trial they said showed donanemab slowed cognitive and functional decline in people with early symptomatic Alzheimer’s disease by 35% over 18 months.
About Author
More Stories
Scientists record seismic tremors from title-clinching Liverpool win over Spurs
Elon Musk’s company town: SpaceX employees vote to create ‘Starbase’
Please welcome to the stage … Anita Dump! The Facebook group with the best and worst drag names